Abstract
Fifty-six patients with disseminated malignant melanoma were randomly allocated to two treatment groups. The first group C received combination chemotherapy consisting of DTIC and ICRF 159. The second group (C+I) received the same chemotherapy but were also immunized with 2 X 10(7) irradiated allogeneic melanoma cells mixed with 50 mug of percutaneous BCG. The survival rates in both treatment groups C and (C+I) were not significantly different, and only minor enhancement of the chemotherapy was found in the (C+I) group. A similar pattern of tissue response was observed in both groups: lymph node, skin and, to some extent liver metastases, respond better than other sites.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Newlands, E., Oon, C., Roberts, J. et al. Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma. Br J Cancer 34, 174–179 (1976). https://doi.org/10.1038/bjc.1976.140
Issue Date:
DOI: https://doi.org/10.1038/bjc.1976.140
This article is cited by
-
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy
Journal of Hematology & Oncology (2022)
-
The role of immunotherapy in the management of patients with malignant melanoma
World Journal of Surgery (1979)
-
Chemotherapy of malignant melanoma
World Journal of Surgery (1979)
-
Combined modality therapy of malignant melanoma
World Journal of Surgery (1979)
